The Global Type 1 Diabetes Drugs Market 2016-2020 is a new research report added to ReportsnReports.com. The increased awareness about type 1 diabetes will replicate itself in terms of the rise in the number of people opting for the treatment. National and international awareness campaigns worldwide focus on enhancing diabetes-related knowledge and its management.
Complete report on type 1 diabetes drugs market spread across 80 pages, analyzing 3 major companies and provides 44 data exhibits is now available at http://www.reportsnreports.com/reports/521045-global-type-1-diabetes-market-2016-2020.html
The analysts forecast global type 1 diabetes drugs market to grow at a CAGR of 8.05% during the period 2016-2020. An increase in the type 1 diabetes population is expected to increase the number of people opting for treatment. This will drive the sale and revenue of these drugs. The market for type 1 diabetes drugs is served by insulin-based replacement products, including regular insulin and insulin analogs. Chemically, insulin-based products can be categorized into animal insulin, recombinant human insulin, and insulin analogs.
In this industry report, the analysts have estimated factors such as the increasing awareness of type 1 diabetes to drive this market in the next four years. Several national and international awareness campaigns are held around the world that focus on educating people and enhancing their knowledge about diabetes and its management. Globally, the World Diabetes Day is celebrated on November 14 by over 200 member associations of the International Diabetes Federation (IDF). Such organizations run community and global level programs to educate people about diabetes and the best ways to manage the condition. These programs are mostly conducted in collaboration with other national and international institutes, for instance, Novo Nordisk has initiated a program to educate doctors and patients in China about proper diabetes care.
Order a copy of Global Type 1 Diabetes Drugs Market 2016-2020 report @ http://www.reportsnreports.com/purchase.aspx?name=521045 .
The insulin drugs dominated the market and is expected to hold more than 85% of the market share by the end of 2020. Insulins are further segmented according to their action time into fast-acting insulin, intermediate-acting insulin, and long-acting insulin. Fast-acting insulin is rapidly absorbed into the bloodstream from the subcutaneous tissues. Intermediate-acting insulin is absorbed slowly into the bloodstream, but its effect stays for a longer duration compared to fast-acting insulin. Long-acting insulins are absorbed slowly into the bloodstream. Its peak is minimal and has a stable plateau effect which lasts a day.
During 2015, the Americas dominated the global type I diabetes drugs market and accounted for a market share of close to 62%. The US was the largest revenue contributor to the region because of the growing prevalence of the disease and rise in obesity. The accessibility to therapies by reimbursement programs is further expected to drive the growth of the market in the Americas.
The global type I diabetes drugs market is highly competitive due to the presence of several small and large vendors. The market is open to new players and has a lot of opportunities for growth. The competitive environment is expected to increase in due to the product extensions, new products, and new applications of the products and services provided.
Global Type 1 Diabetes Drugs Market key palyers Eli Lilly and Company, Novo Nordisk A/S, and Sanofi SA. Other Prominent Vendors in the market are: Adocia, Astellas Pharma, AstraZeneca, Baxalta, BHV Pharma, Biocon, Biodel, Boehringer Ingelheim, CureDM, Dance Biopharm, Diamyd Therapeutics AB, Diasome Pharmaceuticals, DiaVac, Exsulin, Gan & Lee Pharmaceuticals, Generex Biotechnology, GlaxoSmithKline, ILTOO Pharma, Intrexon, Islet Sciences, Kamada, Kotobuki Pharmaceutical, Lexicon Pharmaceuticals, Living Cell Technologie, MacroGenics, MannKind Pharmaceuticals, Merck, Merrion Pharmaceutical, Oramed Pharmaceuticals, Osiris Therapeutics, Perle Biosciences, Pfizer, REGiMMUNE, Strongbridge Biopharma, Toleranzia, Tolerio, Xeris Pharmaceuticals, and XOMA.
Further, the report states that besides the high prices and accessibility of insulin-based therapies, the products also have poor storage and distribution policies. Inadequate distribution policies and the lack of a centralized supply chain lead to price variations between countries.
Check for DISCOUNT at http://www.reportsnreports.com/contacts/discount.aspx?name=521045
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Connect With Us on:
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
P: + 1 888 391 5441